Entrada Therapeutics, Inc. utilizes its endosomal escape vehicle (EEV) platform to develop therapeutic programs, such as oligonucleotide, antibody, and enzyme-based programs for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, targeting Duchenne muscular dystrophy and myotonic dystrophy type 1, with other therapeutic developments including EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. Founded in 2016 as CycloPorters, Inc., Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts.